drugset / Trial / NCT00545272

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma

NCT00545272

Phase 2 Completed 392 enrolled Novartis Pharmaceuticals Schering-Plough · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.

Timeline

Start
2007-10
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Formoterol Other / unclassified 12 ug Inhaled
Subject Indacaterol Other / unclassified 62.5 ug Inhaled
Subject Indacaterol Other / unclassified 125 ug Inhaled
Subject Indacaterol Other / unclassified 250 ug Inhaled
Subject Indacaterol Other / unclassified 500 ug Inhaled
Background Salbutamol Unknown 100 ug Inhaled

Indications